摘要
Ubiquitin-conjugating enzyme UBE2C is one of the important members of ubiquitin-proteasome pathway(UPP).Amplification and/or overexpression of UBE2C have been reported in many malignancies,and a high expression of UBE2C is associated with poor clinical outcomes.In this review,the pathological role of dysregulated UBE2C in gastrointestinal cancers and its potential role as a diagnostic and/or a prognostic marker as well as a therapeutic target in these cancers are discussed.
基金
This research is supported by the NSFC grant(81773178)
belongs to stage result of Hebei Provincial Health and Family Planning Commission Project(Key Science and Technology Research Program)with grant number:20171069.
